MURA vs. ALRN, CALC, CARM, VHAQ, KZR, SCYX, KRON, MNOV, IMMX, and YS
Should you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Aileron Therapeutics (ALRN), CalciMedica (CALC), Carisma Therapeutics (CARM), Viveon Health Acquisition (VHAQ), Kezar Life Sciences (KZR), SCYNEXIS (SCYX), Kronos Bio (KRON), MediciNova (MNOV), Immix Biopharma (IMMX), and YS Biopharma (YS). These companies are all part of the "pharmaceutical preparations" industry.
Mural Oncology (NASDAQ:MURA) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
80.2% of Mural Oncology shares are owned by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are owned by institutional investors. 0.1% of Mural Oncology shares are owned by insiders. Comparatively, 5.6% of Aileron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Aileron Therapeutics had 1 more articles in the media than Mural Oncology. MarketBeat recorded 5 mentions for Aileron Therapeutics and 4 mentions for Mural Oncology. Aileron Therapeutics' average media sentiment score of 0.95 beat Mural Oncology's score of 0.38 indicating that Aileron Therapeutics is being referred to more favorably in the news media.
Aileron Therapeutics received 211 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 100.00% of users gave Mural Oncology an outperform vote while only 66.88% of users gave Aileron Therapeutics an outperform vote.
Mural Oncology's return on equity of 0.00% beat Aileron Therapeutics' return on equity.
Mural Oncology presently has a consensus price target of $13.00, suggesting a potential upside of 243.92%. Aileron Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 397.38%. Given Aileron Therapeutics' higher possible upside, analysts clearly believe Aileron Therapeutics is more favorable than Mural Oncology.
Summary
Aileron Therapeutics beats Mural Oncology on 7 of the 10 factors compared between the two stocks.
Get Mural Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mural Oncology Competitors List
Related Companies and Tools
